Document Type
Article
Publication Date
7-19-2021
Publication Title
Institute for Economic Thinking
Volume
Working Paper Series
Issue
No. 133
First Page
1
Last Page
70
DOI
https://doi.org/10.36687/inetwp133
Abstract
The discovery and development of new medicines classically involves a linear process of basic biomedical research to uncover potential targets for drug action, followed by applied, or translational, research to identify candidate products and establish their effectiveness and safety.
This Working Paper describes the public sector contribution to that process by tracing funding from the National Institutes of Health (NIH) related to published research on each of the 356 new drugs approved by the U.S. Food and Drug Administration from 2010-2019 as well as research on their 218 biological targets.
Recommended Citation
Cleary, Ekaterina Galkina; Jackson, Matthew J.; and Ledley, Fred D., 2021. Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019, Institute for Economic Thinking.
Included in
Pharmaceutics and Drug Design Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons
